NCT03453060 - Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

November 25, 2018

Study Completion Date

November 25, 2018

Conditions

Thrombosis

Interventions

DRUG

E-WE Thrombin- Dose 1

Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.

DRUG

E-WE Thrombin- Dose 2

Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.

DRUG

E-WE Thrombin- Dose 3

Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.

DRUG

E-WE Thrombin- Dose 4

Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.

OTHER

Placebo

Participants received a single intravenous dose of placebo.

Trial Locations (1)

Celerion, Tempe